Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. antibiotic use
Show results for
Products
Services
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Antibiotic Use Articles & Analysis

62 news found

Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

The suite of products now includes saccharides, flavonoids, terpenoids, phenylpropanoids, antibiotics, phenols, steroids, and quinones, all of which are invaluable in modern scientific and industrial fields. ...

ByAlfa Chemistry


Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

Infection Control Resources to Safeguard Patients from Vancomycin-Resistant Enterococci and Other Pathogens

The Centers for Disease Control and Prevention (CDC) warns these bacteria are constantly finding new ways to avoid the effects of the antibiotics used to treat those infections. Vancomycin-resistant enterococci (VRE) is the name for the bacteria resistant to the antibiotic known as vancomycin. When the CDC released the 2019 ...

ByCochrane & Associates, LLC


Daptomycin ReadyMade™ Solution to Power Up Spectrum and Microbiology Applications

Daptomycin ReadyMade™ Solution to Power Up Spectrum and Microbiology Applications

Amerigo Scientific, a distributor focused on providing critical products and services to biomedical and life science communities, unveils the addition of the reliable Daptomycin ReadyMade™ Solution to its growing portfolio of innovative products to power up spectrum and microbiology applications. Daptomycin is an essential antibiotic used in the treatment ...

ByAmerigo Scientific


A project led by Vaxdyn receives funding from Next Generation EU Funds

A project led by Vaxdyn receives funding from Next Generation EU Funds

First, to raise specific immunity against one of the most important antibiotic-resistant bacteria in humans populations at hjgh-risk of development of antibiotic-resistant infections. And second, deliver to the porcine industry a vaccine to prevent infections of one of the most important causative agents of respiratory diseases in piglets, for reduction of the ...

ByVaxdyn, S. L.


Photodisinfection successfully eradicates pathogens associated with replacement joint infections

Photodisinfection successfully eradicates pathogens associated with replacement joint infections

[ii] Patients undergoing major surgeries like hip or knee replacements face the risk of life-threatening infections – with the majority of these related to the patients’ own microflora. In the US alone, the annual cost of treating PJIs is estimated at $1.62 ...

ByOndine Biomedical Inc


OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

By combining our respective skillsets, we believe we can not only use diagnostic and surveillance data to help healthcare professionals make better diagnoses, but also expand our options to treat AMR in the future, by targeted repurposing of key antibiotics. ...

ByOpGen, Inc.


Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

The prespecified immunogenicity endpoints of the Phase 2 portion of the study include an assessment of the induction of antibody responses, using immunoglobulin G (IgG) and opsonophagocytic activity (OPA), at each of the three VAX-24 doses and compared to Prevnar 20™ and, for the additional four serotypes contained in VAX-24 and Pneumovax® 23 but not in Prevnar ...

ByVaxcyte, Inc.


The transformation of precision medicine in infectious disease

The transformation of precision medicine in infectious disease

In fact, this precision approach garnered so much attention that d’Herelle and George Eliava co-founded an institute in Tbilisi, Georgia, in 1923 that was dedicated to studying bacteriophages and clinical use of phage therapies. However, this movement’s momentum quickly fizzled out after the discovery of the first antibiotic, penicillin, in 1928. ...

ByLocus Biosciences, Inc.


Profacgen Launched Antibiotic-free Expression System for Protein Expression Service

Profacgen Launched Antibiotic-free Expression System for Protein Expression Service

Expression vectors inserted with antibiotic resistance genes are mainstream recombinant expression systems that use antibiotics during fermentation to avoid the growth and domination of anaplastic granulocytes. ...

ByProfacgen


Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

The prespecified immunogenicity endpoints of the Phase 2 portion of the study include an assessment of the induction of antibody responses, using immunoglobulin G (IgG) and opsonophagocytic activity (OPA), at each of the three VAX-24 doses and compared to Prevnar 20™ and, for the additional four serotypes contained in VAX-24 and Pneumovax® 23 but not in Prevnar ...

ByVaxcyte, Inc.


Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract

Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract

The Veterans Health Administration (VHA) is the largest integrated health care system in the US, providing care at nearly 1,300 healthcare facilities to over 9 million Veterans enrolled in the VA health care program. ...

ByImbed Biosciences


The GRAM paper gives face to the AMR crisis - Vaxdyn’s comment about the GRAM paper

The GRAM paper gives face to the AMR crisis - Vaxdyn’s comment about the GRAM paper

The GRAM paper is the most comprehensive study about the global incidence of antibiotic-resistant bacteria. The relevance of this study is that finally gives a clear face, based on data, to the AMR crisis. ...

ByVaxdyn, S. L.


Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

Pneumococci also cause over 50% of all cases of bacterial meningitis in the United States. Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments. ...

ByVaxcyte, Inc.


Takeover of terraplasma medical GmbH by the Viromed Group

Takeover of terraplasma medical GmbH by the Viromed Group

Cold plasma treatment reduces the use of antibiotics or cortisone and does not cause allergic side effects or pain. ...

Byterraplasma medical GmbH


Specific Diagnostics Announces the Formation of its US Commercial Team and Introduction of the Reveal Rapid AST System to the US Market

Specific Diagnostics Announces the Formation of its US Commercial Team and Introduction of the Reveal Rapid AST System to the US Market

Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, and in tandem with the commencement of clinical and analytical studies in preparation for 510(k) submission to the FDA, Specific’s commercial team will be engaging with leading lab directors across the US to introduce them to the ...

BySpecific Diagnostics


Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children

Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children

While we would like to reduce unwarranted use of antibiotics we do not want to leave a bacterial infection untreated. ...

ByMeMed


Clinical Data of The Visby Medical Sexual Health Click Test Published in Journal of the American Sexually Transmitted Diseases Association

Clinical Data of The Visby Medical Sexual Health Click Test Published in Journal of the American Sexually Transmitted Diseases Association

Rapid and accurate point-of-care results create a better workflow, and can play a pivotal role in preventing the misuse of antibiotics by enabling clinicians to select the most effective treatment for the condition. Appropriate use of antibiotics can improve patient health, reduce health care costs, and prolong the utility of effective ...

ByVisby Medical, Inc.


Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test

Inflammatix Announces Additional $12.1 Million Funding from BARDA for ViraBac EZ Acute Infection Test

ViraBac EZ is intended to help physicians quickly and accurately determine whether to prescribe antibiotics in ambulatory settings. The test will use a capillary blood sample, ideal for use in primary care, urgent care and other outpatient clinical settings. ...

ByInflammatix, Inc.


Vaxdyn introduces its multi-pathogen vaccine candidate KapaVax at the World Vaccine Congress Europe

Vaxdyn introduces its multi-pathogen vaccine candidate KapaVax at the World Vaccine Congress Europe

The primary target population in need will be individuals affected by chronic lung problems in high risk of developing antibiotic-resistant infections by these bacteria. The presentation of Dr. Infante was part of a session of pipeline updates by companies funded by the CARB-X organization (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator; ...

ByVaxdyn, S. L.


MerLion Pharmaceuticals Completes Growth Financing Round

MerLion Pharmaceuticals Completes Growth Financing Round

MerLion Pharmaceuticals GmbH (MerLion), a biopharmaceutical company focused on research and development of novel antibiotics for the treatment of serious bacterial infections, today announced the successful completion of a growth financing round raised via a private placement to European strategic investors. The funds raised will primarily be used to finance ...

ByMerLion Pharmaceuticals GmbH

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT